{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"}],"description":"Progression -free survival (PFS) after initiation of pomalidomide therapy. Progressive disease is defined as increase of \\> 25% from lowest response value in any one or more of the following: Serum M-component and/or (the absolute increase must be \\> 0.5 g/dL); Urine M-component and/or (the absolute increase must be \\> 200 mg/24 h); Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be \\> 10 mg/dL; Bone marrow plasma cell percentage; the absolute percentage must be \\> 10%; Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcaemia (corrected serum calcium \\> 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder.","groups":[{"description":"Pomalidomide: Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.","id":"OG000","title":"Pomalidomide"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year following initiation of pomalidomide therapy","title":"Progression-free Survival (PFS) After Initiation of Pomalidomide Therapy","type":"PRIMARY","unitOfMeasure":"percentage of participants"}